Open Demat Account

50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Delivery and Volume
Similar Stocks

Dr Lal Pathlabs Ltd Performance

Today's Low
Today's High
52 Wk Low
52 Wk High



Traded Value (Cr)

54.28 Cr

Prev. Close






Face Value


Dr Lal Pathlabs Ltd Fundamentals

Market Cap
₹ 19,241 Cr
P/E Ratio (TTM)
P/B Ratio
Debt to Equity
17.01 %
Dividend Yield
Book Value

Click here to know more about Fundamentals

Dr Lal Pathlabs Ltd F&O

Dr Lal Pathlabs Ltd Option Chain

Dr Lal Pathlabs Ltd Financials

Dr Lal Pathlabs Ltd Financials

Dr Lal Pathlabs Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 54.60 % 54.60 % 54.61 % 55.01 %
FII 26.15 % 25.35 % 24.36 % 23.27 %
Mutual Funds 6.79 % 5.88 % 5.36 % 4.92 %
Retail 6.47 % 7.26 % 8.37 % 9.31 %
Others 5.98 % 6.90 % 7.31 % 7.50 %





Mutual Funds










Mutual Funds










Mutual Funds










Mutual Funds






Resistance and Support



First Resistance₹2,350.067
Second Resistance₹2,372.733
Third Resistance₹2,406.417
First Resistance₹2,293.717
Second Resistance₹2,260.033
Third Resistance₹2,237.367

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
1 Month343,346160,81252.12
6 Months353,410133,19337.69

About Dr Lal Pathlabs Ltd

Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests. Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s. Central Clinical Laboratory and M/s. Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt. Ltd.' Dr. Lal PathLabs Limited was incorporated as a a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory is now undertaken by the Company, while Central Clinical Laboratory does not undertake any business operations. The Company converted into a Public Limited pursuant to a Special Resolution of the Shareholders of the Company at an EGM held on August 7, 2015. Consequently, name of the Company was changed to Dr. Lal PathLabs Limited' and a fresh Certificate of Incorporation pursuant to the change of name was granted by the RoC on August 19, 2015. The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the Company with the Company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23, 2018 and December 11, 2018 respectively. Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017 (being the appointed date) and consequently stands dissolved without winding up. The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh. On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017. Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena. During the FY2019, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12, 2018, respectively, as wholly owned subsidiaries of the Company. As on 31 March 2019,the company has 5 domestic and 3 overseas subsidiaries under its roof. The Board of Directors of your Company in their meeting held on February 3, 2020, approved a Scheme of Amalgamation ('the Scheme') between the Company and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal, New Delhi for approval of the Scheme of Amalgamation. During the FY2020, Company's Wholly Owned Subsidiary viz M/s. PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s. APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6, 2019, as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million (Rs 7.10 million) consisting of 9,880 shares of KES 100. As on 31 March 2020,the company has 7 domestic and 4 overseas subsidiaries under its roof. During the year 2019-20, the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares. During the quarter ended 30 June 2020,the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltd,through subscription of additional equity shares. Subsequent to the quarter ended 30 September 2020,pursuant to approval of the Board of Directors of Pathlabs Unifiers Private Ltd(PUPL),a whollyowned subsidiary,PUPL has signed binding term sheets on 06 November 2020,for the acquisition of the business of Bindish Diagnostic Laboratory LLP,Gujarat,on a going concern basis,for a purchase consideration not exceeding Rs 40 million and equity stake of 40% in ChanRe Diagnostic Services Private Ltd,Bengaluru,for a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services. During the quarter ended 31 December 2020, the company has made a further investment of Rs 225 million in its whollyowned subsidiary,Pathlabs Unifiers Private Ltd,through subscription of additional equity shares. Also the company made a further investment of Rs 40 million in its whollyowned overseas subsidiary,Dr.Lal Pathlabs Kenya Private Ltd,through subscription of additional equity shares. During year 2020-21, the Company added 15 labs, 600 collection center and 2200 pick-up points. It had overall 231 clinical labs, 3,705 patient service centres and 9,247 pickup-up points as on March 31, 2021. The Board of Directors of the Company in their meeting on February 3, 2020, approved a Scheme of Amalgamation between Dr. Lal PathLabs Limited (the Transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company (Transferor Company), which was sanctioned on May 13, 2022 and the appointed date for the Scheme is April 1, 2020. During the year 2021-22, the Company acquired 100% stake in M/s Suburban Diagnostics (India) Private Limited and consequently, Suburban became a Wholly Owned Subsidiary of the Company, effective November 12, 2021. It introduced 46 labs, 1,026 patient service centers and 1,352 pick-up points. The Company opened its Reference Lab at Vidyavihar, in Mumbai in Jan' 23. Dr. Lal PathLabs expanded its National Reference Lab in Rohini, Delhi, by acquiring a second electron microscope, an upgraded lab information system and advanced tools such as artificial intelligence and data mining. During FY 2023, the Company operated a network of 277 clinical labs, including the prestigious National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore and Mumbai. Additionally, with 5,102 Patient Service Centres (PSCs) and 10,938 Pick-up Points (PUPs), the Company has established a nationwide presence. APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of Company (APL/ Transferor Company), was amalgamated with Dr. Lal PathLabs Limited (the Company/ Transferee Company) effective on March 27, 2023. The Company launched 134 tests in FY' 23 to expand the Super Specialty Portfolio.

Managing Director

Om Prakash Manchanda



NSE Symbol


Dr Lal Pathlabs Ltd Management

Arvind LalChairman / Executive Director
Vandana LalExecutive Director
Archana Lal ErdmannNon Executive Director
Om Prakash ManchandaExecutive Director & MD
Rahul SharmaNon Executive Director
Anoop Mahendra SinghIndependent Non Exe. Director
Harneet Singh ChandhokeIndependent Non Exe. Director
Sunil VarmaLead Independent Non Executive
Saurabh SrivastavaIndependent Non Exe. Director
Somya SatsangiIndependent Non Exe. Director
Rohit BhasinIndependent Non Exe. Director
Arun DuggalIndependent Non Exe. Director
Gurinder Singh KalraIndependent Non Exe. Director
RAJIT MEHTAIndependent Non Exe. Director

Dr Lal Pathlabs Ltd News

Dr Lal PathLabs appoints Shanka Banerjee as CEO
Dr Lal PathLabs said that its board of directors has approved the re-designation of Shankha Banerjee by appointing him as chief executive officer (CEO) with effect from 21 May 2024.
Dr Lal Pathlabs CEO Bharath U resigns
The healthcare service provider has announced that Bharath Uppilliappan has resigned from the position of chief executive officer (CEO) and key management personnel (KMP) of the company on 3 March 2024.
Dr Lal Pathlabs receives affirmation in credit rating for LT bank facilities
Board of Dr. Lal PathLabs recommends second interim dividend
Of Rs 12 per share
Dr Lal Pathlabs consolidated net profit rises 53.98% in the December 2023 quarter
Sales rise 10.11% to Rs 538.90 crore
Dr Lal Pathlabs gains as Q3 PAT rises 54% YoY to Rs 81 cr
Dr. Lal Pathlabs rose 1.12% to Rs 2,539.80 after the company’s consolidated net profit surged 53.98% to Rs 81.3 crore in Q3 FY24 as compared to Rs 52.8 crore recorded in Q3 FY23.
Dr. Lal PathLabs to conduct board meeting
On 1 February 2024
Dr Lal Pathlabs allots 8,000 equity shares under ESOP
Dr Lal PathLabs spurts as Q2 PAT climbs 53% YoY To Rs 111 cr
Dr Lal PathLabs rallied 3.30% to Rs 2,455.55 after the company's consolidated net profit soared 52.9% to Rs 110.7 crore in Q2 FY24 as against Rs 72.4 crore recorded in Q2 FY23.
Dr Lal Pathlabs consolidated net profit rises 52.44% in the September 2023 quarter
Sales rise 12.65% to Rs 601.30 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
₹ 6,169.55
(1.57 %)
MAXHEALTH₹ 75,114 Cr
₹ 772.85
(-0.67 %)
MEDANTA₹ 37,690 Cr
₹ 1,403.70
(2.24 %)
FORTIS₹ 32,478 Cr
₹ 430.20
(-1.34 %)
ASTERDM₹ 26,004 Cr
₹ 520.60
(-0.23 %)

Dr Lal Pathlabs Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Dr Lal Pathlabs Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Dr Lal Pathlabs Ltd's share price is ₹2,209.20 as of April 19, 2024

Dr Lal Pathlabs Ltd's P/E ratio is 58.32 times as of April 19, 2024.

Dr Lal Pathlabs Ltd's most recent financial reports indicate a price-to-book ratio of 10.86, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Dr Lal Pathlabs Ltd's market is 19,242 Cr as on April 19, 2024.

The current financial records of Dr Lal Pathlabs Ltd show a 17.01% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Dr Lal Pathlabs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Dr Lal Pathlabs Ltd's 52-week high and low as of April 19, 2024 are ₹2237.75 and ₹2165.8 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Dr Lal Pathlabs Ltd stands at 54.60%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 25.35% to 26.15%.